Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elsufavirine + 2 nucleoside reverse transcriptase inhibitors
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Elsufavirine + 2 nucleoside reverse transcriptase inhibitors is a pharmaceutical combination regimen for the treatment of HIV-1 infection. Elsufavirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while the nucleoside reverse transcriptase inhibitors (NRTIs), also called nucleoside analogues, act as chain terminators for HIV reverse transcriptase, preventing viral genome replication. This combination exerts a dual mechanism targeting the same viral enzyme (reverse transcriptase) at different sites, with the NNRTI binding allosterically and the NRTIs acting as competitive substrates for the natural nucleosides. This combination is used as part of standard antiretroviral therapy for HIV-1 infection.
- Brand names
- Elpida + 2 NRTIs
- Other names
- elsulfavirine + lamivudine + tenofovirelsulfavirine + emtricitabine + tenofovir
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseCA2 (Carbonic Anhydrase 2)CA1 (Carbonic anhydrase 1)CA7 (Carbonic anhydrase VII)
Beyond the preview
Go deeper on elsufavirine + 2 nucleoside reverse transcriptase inhibitors.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elsufavirine + 2 nucleoside reverse transcriptase inhibitors.